PharmEasy Share Price 2022 | Pharmeasy Unlisted Share Price

Pharmeasy Share Price Full Details

About the Company

PharmEasy is India’s leading digital healthcare platform. It provides information, consultations, diagnostics tests, medicines, healthcare products, and services from registered and trusted pharmacies, leading diagnostic laboratories, and trusted doctors across India, serving every habitable zip code of the country (Wikipedia).

The journey of PharmEasy was started in 2015, when founders Dharmil Sheth, an MBA from IMT Ghaziabad and Dr. Dhaval Shah, MBBS from Rajiv Gandhi Medical College and MBA from XLRI Jamshedpur, came up with the idea of an online pharmacy to make healthcare affordable and accessible to one and all.

Overview of PharmEasy

They are India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report.

They operate an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages

A. providing digital tools and information on illness and wellness.

B. offering Teleconsultation.

C. offering diagnostics and Radiology tests.

D. delivering treatment protocols including products and devices.

PharmEasy custom-built proprietary technology, unified data platforms, supply chain capabilities, and a deep understanding of the dynamic interplay between the various sub-segments of India’s healthcare market are the capabilities that differentiate us.

These capabilities enable PharmEasy to provide each stakeholder in the healthcare value-chain, viz.:

(a) channel (wholesalers, retailers, and chemists/institutions).

(b) consultants (and hospitals), diagnostic and radiology labs.

(c) consumers

(d) companies (pharmaceutical, nutraceutical, medical devices).

The businesses have a presence across the country, with last-mile 163 capabilities to deliver in over 18,587 pin codes (for June 2021) via PharmEasy marketplace, allowing the ability to provide access in an affordable manner to the common man. The platforms have scaled across urban, semi-urban, and rural India, with an ability to serve people across income groups and geographies.

Journey of PharmEasy

2015 – Started the journey in Mumbai and received angel funding.

2016 – Received Series-A funding and expanded into 5 cities. The same year they have started a home-diagnostics service.

2017 – Received Series-B funding and expanded into 700 cities. Launched online delivery of health care products.

2018 – Received Series-C funding and expanded PAN India presence.

2019 – Received Series-D funding and expanded more than 22000+ PIN codes.

2020– It has got merged with Ascent Health and 5 other companies to form API Holdings, to form India’s biggest online healthcare company.

2021 – It has purchased 66% stakes in Thyrocare and this is the first listed company to be acquired by any Unicorn in India.

Currently, there is a team of 4000+ dedicated employees and have more than 10000+ retail stores working 24*7 to ensure medicines are delivered on time and at the best possible prices.

Funding History

March 2016	~34 Crores
March 2017	~104 Crores
April 2017	~13 Crores
February 2018	~13 Crores
September 2018	~350 Crores
September 2018	~2800 Crores
November 2019	~1650 Crores
April 2021	~2400 Crores
June 2021	~150 Crores

Product and Services

If you check the website of PharmaEasy, you will find the following services;

(i) Order Online Medicine

How does it work?

Step-1: The buyer needs to upload the prescription. Once PharmEasy receives it, they verify and send the same to the Medical stores near the pin code.

Step-2: PhameEasy delivery agent then collects medicine from Pharmacy and delivers it to the user.

(ii) Healthcare Products

Similar to buying the medicine you can buy various healthcare products such as Nutritions, Personal care, Skin Care, Ayurvedic Products, Life-Style Ailments Products.

(iii) Diagnostics Tests

Under this service, you can book diagnostics tests under PharmEasy labs. PharmEasy labs is a diagnostic service offered by its partner lab Medlife Labs directly. Medlife is now being acquired by PharmEasy. As they have recently acquired Thyrocare, they are giving the option to book tests for these labs as well.

PharmEasy Business Model

The business model is very simple and straightforward. It connects buyers, suppliers, and distributors. Buyer has the option to choose services such as Medicine, Health-Care Products, book diagnostic tests, etc from the application and website.

They get 1-2% commission on selling medicines, they get advertisement money for displaying products of various pharmaceuticals, Nutraceuticals, companies, etc., and also get income from diagnostics tests.

<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span>

DRHP of PharmEasy

PharmEasy Share Price Movement

Source: UnlistedZone App

Note: Above Pharmeasy Share Price Graph is taken on 25th Jan 2021. For updated Pharmeasy unlisted share price, please consider downloading and installing our Android App. You can also check the live prices and historical prices of other unlisted shares currently trading in unlisted markets of India.

PharmEasy Unlisted Shares Details:

Total Available Shares:	10000
Face Value:	₹ 1 Per Equity Share
ISIN:	INE0DJ201029
Lot Size:	100 Shares
Current Unlisted Share Price:	₹ 64 Per Equity Share

Promoters And Management:

Management Team	Qualification	Designation	Experience
Siddharth Bhaskar Shah	MBA, IIM A	Co-founder, Managing Director and Chief Executive Officer
Harsh Shailesh Parekh	MBA,NMIMS	Co-founder and Whole-time Director	Bharti Airtel
Dharmil Sheth	MBA, IMT G	Co-founder and Whole-time Director	MakeMyTrip,
Dhaval Rajesh Shah	MBBS,MBA(XLRI)	Key Management Personnel	McKinsey and Company
Hardik Dedhia	Master of Computer Engineering, Carnegie Mellon	Key Management Personnel	NetApp,Ascent Health
Ankur Thandani	B.Tech,ENTC	Non executive director	RISE fund
Aditya Puri	CA,ICAI	Chairman and Non executive director	HDFC bank(MD)
Ashutosh Sharma	MBA,Booth School	Non executive director
Savita Sharma	PGDM,Symboisis	Chief HR	M&M, Bharti Airtel
Akash Bharadwaj	B.Tech,MBA	Chief Strategy Officer	91Streets,Goldman Sach

Shareholding Pattern:

Name of Shareholders	No.of Shares	% of holding
Siddharth Shah	89,176,340	1.32
Dharmil Sheth	18,269,329	0.30
Harsh Parekh	17,037,456	0.28
Naspers Ventures BV	813,316,570	12.04
Macritchie Investments Pte. Ltd	732,516,290	10.84
TPG Growth V SF Markets Pte. Ltd.	449,492,340	6.65

Financials of PharmEasy Unlisted Shares:

Particulars (Fig. In Cr)	2016	2017	2018	2019	2020	2021	Jun-21
Revenue from Operation	0.14	33	111	358	667	2335	1100
Other Income	0.08	0.87	2.58	5.62	70	25	100
Total Revenue	0.22	34	114	363	737	2360	1200
Purchases	0.75	42	118	377	700	2266	1234
Change in Inventory	-0.59	-9.82	-11	-42	-58	-114	-126
Employee Benefit Exps	4	14	38	80	137	270	165
Other Exps	7	34	63	185	275	481	215
EBITDA	-11	-47	-97	-243	-386	-569	-292
OPM	-7319.05%	-141.73%	-87.65%	-67.82%	-57.85%	-24.38%	-24.45%
Finance Cost	0.07	0.18	2.86	5.12	12	43	20
Depreciation	0.23	1.26	3.74	6.24	19	32	17
Profit Before Tax	-11	-48	-101	-248	-347	-620	-319
Tax Exps	0.01	0.07	-2	-5	-11	21	-6
Profit After Tax	-11	-48	-100	-243	-335	-641	-313
NPM	-7415.27%	-143.67%	-90.19%	-67.92%	-50.23%	-27.46%	-26.23%
EPS (Basic)	-93	-415	-865	-2090	-12	-2	-0.77

Valuation of PharmEasy Unlisted Share Outstanding Shares = 610 Crores PharmEasy Unlisted Share Price = 68 per share ( as on 27.04.2022) Mcap = ~42000 Crores or $5.6 Billion. PharmEasy Research Report

Comparison With Peers:

Companies	Mcap	Revenue	EPS	P/S
NetMed	6,200.00	77.00	NA	80.51
Hims(USA)	$1,200.00	$148.00	NA	8.10

Valuation and Peer Learning In India, currently there are no listed peers to compare with. However, Net-Med in the same business was recently acquired by Reliance Industries and one US based listed company almost in the similar business is taken for peer comparison. Net-Med Deal NetMed was acquired by Reliance Industries in August-2020 for Rs. 622 Crores. The Netmeds Marketplace, the B2C e-commerce unit of online pharmacy, saw its total income decline by 44% to INR 7.7 Cr in FY20 from INR 13.93 Cr in the fiscal year 2018-19 (FY19). In FY20, they have revenue of just 7.7 Crores. So, we can assume that deals happened at P/S of 80x. American Listed Company Hims & Hers Health, Inc. is an American telehealth company that sells prescription and over-the-counter drugs online, as well as personal care products. The company is currently trading at P/S of 8.10x.

Company Address:

Frequently Asked Questions:

Please find below the procedure for buying PharmEasy Unlisted Shares at UnlistedZone.

1. You confirm booking of PharmEasy Unlisted Shares with us at a trading price.
2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
3. We will provide the bank details.
4. You need to transfer funds in that account.
5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
6. Payment has to be done from the same account in which shares are to be credited.
7. We will transfer the shares in 24 hours if funds are credited before 2 pm.

Important Note: Please note that the lock-in period for selling PharmEasy Unlisted Shares is 6 months after listing. Hence you can’t sell PharmEasy Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date. For any queries, please contact us at sales@unlistedzone.com

Please find below the procedure for selling PharmEasy Unlisted Shares at UnlistedZone.

1. We will confirm our buying price of PharmEasy Unlisted Shares.
2. We will give you our client master report and you will transfer the PharmEasy Unlisted Shares to our demat account.
3. We will ask for bank details of yours once the PharmEasy Unlisted Shares are received in our demat account..
4. We will transfer the funds in your bank account within 24 hrs of receiving the PharmEasy Unlisted Shares.
5. Payment will be made in RTGS / NEFT / CHEQUE TRANSFER/IMPS. No CASH DEPOSIT.
6. Payment will be given in the same account which is linked to demat account or you need to provide the cancelled cheque shows your name to verify. As per SEBI regulations, the transfer of funds in the third party account is not legal and our policy refrain us from doing so.

Note: The price at which we are buying the share is fixed for 3 days. If you cant sell your stock within 3 days, then the price of that day will be applicable when we receive shares in our demat.

Lock-in period of PharmEasy Unlisted Shares depends upon category of investors.

1. Venture Capital Funds or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of PharmEasy Unlisted Shares.
2. AIF-II - There is no locking period.
3. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of PharmEasy Unlisted Shares.

This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

DIS - Delivery Instruction Slip is the way through which an investor can sell or transfer the PharmEasy Unlisted Shares from his/her demat account to any other demat account. There are two Types of DIS Slip.

1. Offline-DIS - This is an offline mode of transfer of shares wherein the investors needs to fill DIS form and give it to their broker for transferring the shares. Following are the fields which are required to be filled.
- a. ISIN number of PharmEasy Unlisted Shares.
- b. Name of PharmEasy Unlisted Shares
- c. Quantity of PharmEasy Unlisted Shares
- d. Cosideration Amount
- e. Target DP ID and Client ID
- f. Annexure
2. Online DIS - Some of the broker these days gives facility of transferring the PharmEasy Unlisted Shares via online DIS. So, please check with your broker whether such facility is available or not. For example: Angel Broking proivdes the facility of Online-DIS from its platform. As an investor he/she simply needs to add a beneficiary into it and send the PharmEasy Unlisted Shares by filling the details similar to Ofline-DIS.

Read our article to understand more about this. https://unlistedzone.com/how-do-i-sell-my-unlisted-shares/

In the last 4-5 years, the unlisted share market has become quite big and as a result of that, the ticket size has reduced from usual 5-10 Lac to 35-50k in today's scenario. So, via our UnlistedZone platform, if somebody wants to buy PharmEasy Unlisted Shares then minimum investment would be 35-50k.

Yes, buying and selling of unlisted shares in India is 100% legal.

If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unlisted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.

If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 20% with indexation benefits.

After listing of shares, the unlisted shares which you have bought through unlisted market, will be taxed at listed rates, if sold through exchange. So, taxes of listed market will be applicable. And, to calculate holding time, for determining LTCG or STCG, the purchase date of unlisted shares will be applicable.

If you buy PharmEasy Unlisted Shares from UnlistedZone then these shares can checked in two ways. However, before we tell you the process of checking of shares, it is intimated that as per SEBI regulations, the shares can be transferred in demat account only.

Check credit of PharmEasy Unlisted Shares Instantly?

1.You can download the NSDL or CDSL application from google play-store and check. If you want to check whether your stock broker is registered with NSDL or CDSL then check the following procedure.
By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
Demat Account = DP ID + Client ID. (16 Characters )
"DP ID is the unique identification of the Broker. Every broker gets a unique number from CDSL or NSDL.By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
Client ID is the unique identification of the Client. Every client gets this unique number which represents his/her portfolio.
In CDSL, all these characters are numbers (1234567891234567) first 8 digits are DP ID and next 8 digits are Client Id whereas in NSDL the first two characters are letters which are in accordance with the country that you are from (IN12345678912345), then 6 unique digits for Broker and next 8 digits are client ID.
Example:
CDSL = 12345678(DP ID) and 91234567(Client ID).
NSDL = IN123456 (DP ID) and 78912345(Client ID).
Check in brokers application?
Credit of PharmEasy Unlisted Shares can be checked in brokers application as well but it takes T+2 days to show the shares.

The PharmEasy Unlisted Shares are credited in demat account same day of transferring funds in our company's bank account.

The price of PharmEasy Unlisted Shares can be checked in two ways. First, you can join our telegram channel where on daily basis we share the latest prices of all the unlisted shares in the morning and secondly, you can register on UnlistedZone.live platform to see the historical graphs and prices of all the shares at one place.

If you see the thesis of investment in the unlisted shares then it is being done mainly to take the advantage of IPO market. And, if the IPO plans of company get delayed due to market conditions or any other reason then demand suddenly drops in the market. The unlisted market works mainly on demand and supply and if there is no IPO news then getting exit would be difficult.

"UnlistedZone is India's fastest and leading marketplace to buy and sell unlisted shares. In the last 3 years, we have already served more than 1 million users on the platform. The total transactions value done from the platform is already more than 100 Crores. The name of our Co-founders Mr. Umesh Paliwal and Dinesh Gupta publish regularly in leading newspapers like MoneyControl, Business-Standard, ET etc for their views on IPO and Unlisted market. In the last 3 years, UnlistedZone has made a good name for itself in the industry and gained a trust of their users. So, the new investors should not be worried about any kind of fraud that is mostly happens with unkown brokers in the market while doing investment with UnlistedZone."

We at UnlistedZone do the valuation based on 2 methods.

1. We check the last funding that is being done in the PharmEasy Unlisted Shares to ascertain the benchmark valuation.
2. If there is no funding happened in the company, then we try to find a business similar to PharmEasy Unlisted Shares in the listed space and do comparison method to ascertain the valuation.

As an investor in the unlisted space, we would always recommend that you must check all the risk parameter carefully before investing in the unlisted space.

We source shares either from the employees or initial investors looking to liquidate their PharmEasy Unlisted Shares.

Pre-IPO shares means which are planning for an IPO in near future. So, all the shares which are traded on the platform are not Pre-IPO Shares. However, if the company's business is going good and then demand will always be there in the unlisted space, so even if the IPO does not come, the investors can easily liquidate their PharmEasy Unlisted Shares in the unlisted market itself.

Rules and regulations of SEBI are applicable in the Unlisted space like lock-in period of 6 months, paying of Stamp Duty, and DP Charges for every transaction etc. However, to become an unlisted broker there is no such regulation by SEBI as of yet.

For tracking news and other information about PharmEasy Unlisted Shares, one can visit our website wherein we post news and other information on daily basis and one can also join our telegram channel.

Discussion on PharmEasy Unlisted Shares:

19 Comments

AKOOL

11:30 PM, 4 May 2022

Apollo Hospitals Enterprise which runs a competitor platform called Apollo 247, along with the biggest hospital chain, biggest pharmacy chain, diagnostic services, specialty clinics, telehealth, R&D centres – everything built in-house and profitable – is currently valued around $7 billion. Why should I buy a cash burning medicine delivery company at $5.6 billion valuation?

Log in to Reply
India2000

10:57 PM, 11 April 2022

What is the fate of this company now? Can it survive Reliance (since Netmeds is owned by reliance)?

Log in to Reply

Umesh Paliwal

12:37 PM, 2 May 2022

Yes, Pharmeasy is a brand. It has 50% market share and Net-med is only at 15%.

Log in to Reply

sk shetty

10:24 AM, 3 January 2022

What is the p/s ratio of pharmeasy ?

Log in to Reply

Umesh Paliwal

3:37 PM, 3 January 2022

Expected Revenue in FY22 = ~6000 Crores…

Mcap at Rs.115 = Rs. 70000 Crores…

Mcap/Sales = 11.67x…

Log in to Reply

Umesh Paliwal

6:23 PM, 24 December 2021

Summary of objections faced by PharmEasy to date

September 2020: PharmEasy’s merger with MedLife merger was approved despite opposition from the SCDA which had argued that online pharmacies were not allowed under the law, and hence the CCI cannot permit “combination for an illegal purpose”. In a representation to the CCI, the association had said that the proposed merger is essentially “that of two e-pharmacies as well as companies involved in the distribution chain”. It also said that the deep discounting by e-pharmacies can harm competition, given that these “are not based on any efficient business model but solely due to cash burn thanks to investment from foreign-based entities”.

July 2021: PharmEasy’s acquisition of Thyrocare was opposed by SCDA in a letter sent to CCI asking the regulatory body to reject the acquisition because e-pharmacies are not legal under Indian law and therefore the proposed acquisition needs to be rejected. It also claimed that allowing PharmEasy to acquire Thyrocare would result in dominance in the market by API Holdings.

November 2021: SCDA again asked SEBI to reject the initial public offering (IPO) of PharmEasy on the grounds that online pharmacies are not legal under Indian law as per a letter sent by the association. The association lists the same reasons as it does in the petition in pleading its case.

December 2021: The Confederation of All India Traders (CAIT) wrote to SEBI a few weeks ago asking the regulator to reject the initial public offering (IPO) of API Holdings, owner of PharmEasy, arguing that the online pharmacy’s business model is “entirely based on gross illegality.”

Log in to Reply
indianfriendszone

8:46 AM, 14 December 2021

Medplus Health being Second Largest pharmacy retailer …. valued at around $1.2-1.3B
can we compare this with Pharmeasy from unlisted stock (at 110-120/- per share) is valued at $9-10B
?
I have heard good review about Medplus compared to other options…

Pharmeasy Total Revenue for March 2021 = 2360cr
Net Profit = -641cr (loss)

As mentioned in Medplus IPO Total Revenue Rs. 3090.81 cr. / Rs. 63.11 cr. for March 2021

Log in to Reply

Umesh Paliwal

11:38 AM, 14 December 2021

PharmEasy FY22 revenue would be ~6400 Crores….First Quarter Results for FY22, PharmEasy has posted ~1600 Crores revenue….

And, PharmEasy is not only an online Pharmacy but complete ecosystem…..

Having said that, the valuation at CMP looks fully-priced in…

Log in to Reply

indianfriendszone

6:33 AM, 18 November 2021

Around One month back Pharmeasy raised fund at $5.6B
and today @130/- it is almost approx valued at $10.6B

Pharmeasy has already filed for IPO… so i just hope it doesnt happen like Policy Bazar and Paytm.

Just before IPO all such startups has given negative returns… even Finopay..

So always better to enter much before IPO… atleast minimum a year

Log in to Reply
varunsingh01

11:16 AM, 15 November 2021

Hi, I am interested to buy. could you please share the price ?

Log in to Reply

Umesh Paliwal

2:40 AM, 16 November 2021

Hi, Current market price of Pharmeasy is Rs.130 per share.

Log in to Reply
pavan kumar

2:09 PM, 7 December 2021

availabe @128

Log in to Reply

indianfriendszone

8:01 AM, 9 November 2021

What is the price ?

Log in to Reply

pavan kumar

4:38 PM, 7 December 2021

available @ 128/share..

Log in to Reply

indianfriendszone

11:52 AM, 31 October 2021

Hello
Do u have the lastest Shareholding Pattern and Balance Sheet?

Log in to Reply

Umesh Paliwal

5:54 AM, 1 November 2021

Not yet..

Log in to Reply

Umesh Paliwal

12:01 PM, 29 October 2021

PharmEasy, India’s largest online pharmacy, has nearly doubled its revenue in FY20 to Rs 637 crore although its losses also increased during the same period, according to documents viewed by Moneycontrol.

PharmEasy’s trading entity, run by Thea Technologies Pvt. Ltd, earned Rs 637 crore in FY20 – compared to Rs 340 crore in FY19, according to its unaudited financial statements. Its losses before tax for the period also doubled to Rs 100.7 crore from Rs 50 crore a year earlier.

The FY20 numbers, ending March 31, only factor in a small portion of the coronavirus lockdown while the last six months have been a busy time for the industry amid fundraises, acquisitions and orders going through the roof.

Compared to other online pharmacies, at least on paper, PharmEasy has been able to keep its cash burn and losses in check. A loss of Rs 100 crore on revenue of Rs 640 crore of revenue is better compared to rivals Medlife (which PharmEasy is acquiring) and Sequoia Capital-backed 1mg. For FY19. Medlife’s revenue grew 165% to Rs 363 crore, on a loss of Rs 404 crore, while 1mg more than doubled to Rs 240 crore in FY19, while losses also almost doubled to Rs 170 crore.

Log in to Reply
Umesh Paliwal

11:57 AM, 29 October 2021

Online pharmacy PharmEasy’s parent will buy a 66.1% stake in diagnostic chain Thyrocare Technologies for ₹4,546 crore, in a sign that Indians are increasingly using mobile apps for their healthcare needs.

Log in to Reply
Umesh Paliwal

11:49 AM, 29 October 2021

In 2019, to give competition to Reliance Retail acquired Net-Meds, Amazon, Flipkart etc. 5 companies decided to merge and formed an alliance called API Holdings and PharmEasy was one of them.

Log in to Reply

Leave a Reply Cancel reply

You must be logged in to post a comment.

error: Content is protected !!